Skylark Bio Added Gene Therapy for Angelman Syndrome
The Cambridge-based company has expanded its development pipeline to include a new candidate for the rare genetic disorder.
Updated on Sept. 24, 2026 in Autism
Live Poll
Do you trust that pharmaceutical companies are sufficiently prioritizing the development of treatments for rare diseases?
Skylark Bio has added a new gene therapy candidate, SKY-AS, to its development pipeline to treat Angelman syndrome. This initiative marks the first central nervous system development program for the Cambridge-based firm.
Why it matters
Angelman syndrome is caused by a loss of UBE3A gene function in neurons, and there are currently no approved disease-modifying therapies available for patients. By restoring UBE3A expression, this program aims to address the root cause of the condition.
Angelman syndrome affects approximately 1 in 15,000 people globally, with an estimated 20,000 individuals living with the condition in the United States. No disease-modifying therapies are currently approved.
The players
Skylark Bio
This Cambridge-based biotechnology company focuses on developing genetic medicine platforms.
Edwin J. Weeber
He recently joined the firm as a Scientific Advisor to provide expertise on the new program.
The details
The SKY-AS therapy utilizes an engineered capsid to deliver a functional copy of the UBE3A gene directly to neurons. This approach enables broad transduction and targeted microdose delivery to the central nervous system.
Timeline
September 24, 2026: Skylark Bio announced the expansion of its development pipeline to include the SKY-AS program.
The Big Picture
The announcement follows a broader industry trend of showcasing specialized genetic platforms at the Alliance for Regenerative Medicine Meeting on the Mesa. The company intends to present its genetic medicine platform at this upcoming industry event.
This development represents a potential future treatment option for those diagnosed with Angelman syndrome. Currently, patients and their families remain limited to existing supportive care as the program advances through its initial studies.
The takeaway
The addition of SKY-AS highlights the shift toward targeted gene therapies for rare neurological conditions that lack current treatment standards. Families affected by the syndrome should track updates on IND-enabling studies to monitor the program progress.
Further reading
Learn more about advancements in neurological research on the Autism page.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust that pharmaceutical companies are sufficiently prioritizing the development of treatments for rare diseases?
